EUCTR2010-024624-20-GB进行中（未招募）1 期
A Pilot Study Investigating the Sensitivity of 18F-labelled Sodium Fluoride PET-CT for Detecting Skeletal Metastases in Renal Cell Carcinoma compared to Planar Bone Scintigraphy and Multidetector CT - 18F-Fluoride PET-CT for Detecting Bone Metastases in RCC
Cambridge University Hospitals NHS Foundation Trust and University of Cambridge0 个研究点开始时间: 2011年4月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Metastatic (Stage IV) renal cell carcinoma of the kidney with known or suspected bone metastasis. Known metastases may have been identified using any imaging modality (e.g. plain film, bone scintigraphy, CT, MRI). For the purposes of this study, bone metastases may be suspected if there is bone pain, a bone mass or neurological symptoms felt to be due to bone metastases. Male or female, 18 years of age or older. Life expectancy of 12 weeks or greater. ECOG performance status 0, 1 or 2. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. Before patient registration, written informed consent, must be given according to ICH/GCP, national and local regulations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Diagnosis of any other malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, or in situ cervical cancer. Allergy to methylene diphosphonate used in bone scintigraphy. Any metabolic disorder that involves the skeletal system. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness. Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to imaging. Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or in the judgment of the investigator would make it undesirable for the patient to enter the trial.
研究者
相似试验
进行中（未招募）
1 期
Experimental study to evaluate the effect of PET/TC using 18F-PSMA label in the management of patients with prostate cancer.MedDRA version: 20.0Level: LLTClassification code 10029002Term: Neoplasm of the prostateSystem Organ Class: 100000004864Prostate cancerEUCTR2019-002000-41-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS500
招募中
不适用
Clinical study to evaluate the usefulness of 18F-FBPA-PET for patient selection and expanding indication for BNCTHead and Neck Cancer,Malignant gliomaJPRN-UMIN000035976Southern TOHOKU BNCT Research Center20
进行中（未招募）
1 期
Domestic Phase I/IIa Investigator-initiated Clinical Trials to Evaluate the Safety of 18F-PSMA-1007 in Healthy Adults and Subjects with Prostate CancerJPRN-jRCT2032210711Tateishi Ukihide13
尚未招募
不适用
ew diagnostic techniques in liver cancerhepatocellular carcinoma (HCC)Cancer - LiverACTRN12613000194763Department of Nuclear Medicine30
已完成
不适用
18F-labelled sodium fluoride positron emission tomography - computed tomography (PET-CT) for renal cell carcinoma (RCC)Renal cell carcinomaCancerISRCTN66828876Cambridge University Hospitals NHS Foundation Trust and University of Cambridge (UK) - Joint Sponsorship20